Exclusion criteria:
|
1. Transient tachyarrhythmia caused by tobacco, alcohol, coffee, fatigue, infection, fever, anemia, drug-induced electrolyte disturbance (such as low potassium), etc.
2. It is hereditary arrhythmia, tachyarrhythmia combined with severe angina pectoris, premature ventricular contractions with a short combined rhythm interval of <300 ms, supraventricular tachycardia with an attack lasting more than 24 hours, new onset atrial flutter, first-diagnosed atrial fibrillation, Pre-excitation combined with atrial fibrillation is accompanied by rapid ventricular rate, continuous ventricular tachycardia (the duration of ventricular tachycardia >= 30s), torsade de pointes type ventricular tachycardia, etc.
3. Patients who have non-drug anti-arrhythmic indications such as catheter ablation, electrical cardioversion, and willingness to operate.
4. Patients with pacemaker implantation or perioperative period.
5. Acute myocardial infarction, severe cardiac insufficiency (NYHA cardiac function class III, IV or LVEF<40%).
6. Patients who have taken sedative, hypnotic, anti-anxiety, and antidepressant drugs in the 4 weeks before the trial.
7. Suicidal attempts or suicidal tendencies (HMD item 3 score >= 2 points).
8. Patients with obvious hemodynamic disorders, syncope, hypotension, and shock.
9. Severe mental disorders or other reasons unable to cooperate.
10. Patients with severe liver, kidney, hematopoietic system and other primary diseases and dysfunctions.
11. Women who are pregnant, preparing to become pregnant or breast-feeding.
12. Patients who have participated in other clinical trials in the past 3 months.
|